Milk powder composition containing breast milk oligosaccharide and easy to digest and absorb and application of milk powder composition

Abstract

The invention provides a milk powder composition containing breast milk oligosaccharide and easy to digest and absorb. The milk powder composition comprises the breast milk oligosaccharide, OPN, galactooligosaccharide, lactoferrin, alpha-whey protein, multivitamins, lactose, vegetable oil and compound minerals, wherein the weight ratio of the lactoferrin to the OPN to the breast milk oligosaccharide to the galactooligosaccharide is 1: (2-4): (2-50): (4-100). The composition can effectively recover and improve the intestinal barrier function caused by inflammatory factors, can be well absorbed by infants with poor digestion and absorption functions, reduces diarrhea and promotes skeletal development.

Description

Technical Field

[0001] The present invention belongs to food compositions, and particularly relates to a milk powder composition containing human milk oligosaccharides that is easy to digest and absorb and its applications. Background Art

[0002] Human milk oligosaccharides (HMO) are the third largest solid component in human breast milk, second only to lactose and fat. Human milk oligosaccharides are free oligosaccharides composed of 3 - 22 monosaccharide units. Human milk oligosaccharides are mainly composed of three major categories: (1) fucosylated oligosaccharides, with 2'-fucosyllactose and 3'-fucosyllactose as representative substances; (2) sialylated oligosaccharides, with 3'-sialyllactose and 6'-sialyllactose as representative substances; (3) oligosaccharides formed by core sugar chain structures without fucosyl or sialyl groups, with lacto-N-tetraose and lacto-N-neotetraose as representative substances.

[0003] There have been many studies on the use of human milk oligosaccharides in infant nutrition foods. For example, patent CN112514997A discloses the use of human milk oligosaccharides to improve the health of the intestinal microenvironment. This patent uses the addition of human milk oligosaccharides, especially fucosylated oligosaccharides 2'-FL or 3-FL, in foods to lower the pH to maintain the intestinal microenvironment and reduce branched-chain fatty acids, thereby improving the health of the intestinal microenvironment; patent CN112869168A discloses a probiotic prebiotic composition with enhanced gastrointestinal immune capacity. The composition includes Lactobacillus paracasei and human milk oligosaccharides, where the human milk oligosaccharides are composed of 2'-fucosyllactose, 3'-fucosyllactose, lacto-N-tetraose, 3'-sialyllactose, and 6'-sialyllactose. This composition can effectively enhance gastrointestinal immune capacity. Patent CN112075637A discloses a composition made from Bifidobacterium and human milk oligosaccharides, where the human milk oligosaccharides include 2'-fucosyllactose (2'-FL), 3'-fucosyllactose (3'-FL), lacto-difucosyllactose (DFL / LDFT), lacto-N-fucosylpentose I (LNFP-I), lacto-N-fucosylpentose II (LNFP-II), lacto-N-fucosylpentose III (LNFP-III), lacto-N-tetraose (LNT), lactoyl-N-neotetraose (LNnT), 3'-sialyllactose (3SL), 6'-sialyllactose (6SL), sialyllactosyl-N-tetraose (LST), and / or disialyllactosyl-N-tetraose (DS-LNT). This composition has the effects of reducing the production of intestinal gas in infants; and / or inhibiting the overgrowth of gas-producing Clostridia in infants' intestines, thereby optimizing and improving the intestinal flora of infants with flatulence and colic.

[0004] The above compositions mainly focus on the role of improving the intestinal microenvironment. However, for some infants with intestinal barrier function damage caused by inflammation or relatively poor congenital spleen and stomach function, studies have found that different compositions containing human milk oligosaccharides have significant differences in the recovery of intestinal barrier function damage and absorption function in infants. Therefore, it is necessary to develop a milk powder composition containing human milk oligosaccharides that can effectively improve the above problems. Summary of the Invention

[0005] The object of the present invention is to provide, in view of the deficiencies of the prior art, a milk powder composition containing human milk oligosaccharides that is easy to digest and absorb. This composition is suitable for infants, especially those with intestinal barrier function damage caused by inflammatory factors or poor digestion and absorption function, and can restore and improve intestinal barrier function, reduce diarrhea, and promote bone development.

[0006] To achieve the above object of the invention, the present invention provides the following technical solutions:

[0007] A milk powder composition containing human milk oligosaccharides that is easy to digest and absorb, which includes human milk oligosaccharides, OPN, galactooligosaccharides, lactoferrin, α-lactalbumin, compound vitamins, lactose, vegetable oil, and compound minerals; wherein the weight ratio of lactoferrin, OPN, human milk oligosaccharides, and galactooligosaccharides is 1: 2 - 4: 2 - 50: 4 - 100.

[0008] Further, the weight ratio of lactoferrin, OPN, human milk oligosaccharides, and galactooligosaccharides is 1: 2 - 4: 2 - 50: 50 - 100.

[0009] Further, based on 100 parts by weight of the total weight of the milk powder composition, it includes 0.03 - 0.2 parts of lactoferrin, 0.02 - 10 parts of human milk oligosaccharides, 0.04 - 0.8 parts of OPN, 1 - 24 parts of galactooligosaccharides, 0.1 - 20 parts of α-lactalbumin, 0.02 - 1 part of compound vitamins, 30 - 60 parts of lactose, 2 - 30 parts of vegetable oil, and 0.02 - 2 parts of compound minerals.

[0010] Even further, based on 100 parts by weight of the total weight of the milk powder composition, the milk powder composition includes 0.03 - 0.2 parts of lactoferrin, 0.02 - 2 parts of human milk oligosaccharides, 0.04 - 0.8 parts of OPN, 1 - 6 parts of galactooligosaccharides, 0.1 - 20 parts of α-lactalbumin, 0.02 - 1 part of compound vitamins, 30 - 60 parts of lactose, 10 - 30 parts of vegetable oil, and 0.4 - 2 parts of compound minerals.

[0011] Furthermore, the human milk oligosaccharide is one or more of 2'-fucosyllactose (2'-FL), 3'-fucosyllactose (3'-FL), 3'-sialyllactose (3SL), 6'-sialyllactose (6SL), lacto-difucotetraose (DFL / LDFT), and lacto-N-fucopentaose I (LNFP-I).

[0012] Furthermore, the weight ratio of the human milk oligosaccharide to OPN is 1:18.

[0013] Even further, the human milk oligosaccharide is 2'-fucosyllactose.

[0014] Furthermore, the compound vitamin includes one or more of vitamin C, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin A, vitamin K, vitamin D, vitamin E, and niacin.

[0015] As a preferred embodiment, per 100 g of the milk powder composition, it contains vitamin C: 62.0 - 84.3 mg;

[0016] vitamin B1: 409 - 584 μg;

[0017] vitamin B2: 624 - 1023 μg;

[0018] vitamin B6: 227 - 314 μg;

[0019] vitamin B12: 1.04 - 1.67 μg;

[0020] vitamin A: 374 - 486 μg RE;

[0021] vitamin K1: 26.4 - 44.2 μg;

[0022] vitamin D: 12.4 - 12.9 μg;

[0023] vitamin E: 4.00 - 8.58 mg α-TE;

[0024] niacin 2735 - 3223 μg.

[0025] Furthermore, the vegetable oil is one or more of soybean oil, palm oil, coconut oil, sunflower oil, and peanut oil.

[0026] Furthermore, the milk powder composition further comprises probiotics. Based on 100 parts by weight of the milk powder composition, the content of the probiotics is 0.01 - 2 parts; and / or the probiotics are Bifidobacterium, preferably Bifidobacterium subsp. Bb-12; the addition amount of the probiotics is further preferably 0.02 - 0.5 parts; for example, 0.05 parts, 0.075 parts, 0.1 parts, 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts; more preferably 0.02 - 0.2 parts.

[0027] Furthermore, the compound minerals are one or more of sodium, potassium, copper, magnesium, iron, zinc, manganese, calcium, phosphorus, calcium, iodine, chlorine, and selenium.

[0028] As an embodiment, per 100 g of the milk powder composition, it contains: magnesium: 354 - 468 mg; iron: 72 - 108 mg; zinc: 83 - 142 mg; manganese: 2100 - 2500 μg; iodine: 516 - 973 μg; copper: 2080 - 3940 μg; selenium: 167 - 234 μg, calcium 16 - 28 μg.

[0029] Compared with the prior art, the present invention has the following beneficial effects:

[0030] The milk powder composition provided by the present invention can effectively restore and improve the intestinal barrier function caused by inflammatory factors. At the same time, for infants and young children with poor digestive and absorption functions, it can be better absorbed, reduce diarrhea, and promote bone development. Detailed Embodiments

[0031] The following non-limiting examples can enable those of ordinary skill in the art to more comprehensively understand the present invention, but do not limit the present invention in any way. The following content is merely an exemplary illustration of the scope claimed by the present invention. Those skilled in the art can make various changes and modifications to the invention according to the disclosed content, and it should also fall within the scope claimed by the present invention. Unless otherwise specified, the unit "part" in each embodiment of the present invention refers to parts by weight.

[0032] Example 1

[0033] A formula milk powder composition has the following formula:

[0034] Raw material name Usage (parts) Human milk oligosaccharide (2'-FL) 1.8 OPN 0.1 Galactooligosaccharide 2.5 α-Lactalbumin 11.95 Lactoferrin 0.05 Compound vitamin 0.07 Lactose 52.91 Soybean oil 30 Compound mineral 0.6 Probiotic 0.02 Total 100

[0035] Among them, the weight ratio of lactoferrin, OPN, human milk oligosaccharide, and galactooligosaccharide is 1:2:36:50.

[0036] The so-called compound vitamins, per 100 g of the milk powder composition, contain vitamin C: 62.0 mg;

[0037] Vitamin B1: 409 μg;

[0038] Riboflavin: 800 μg;

[0039] Pyridoxine: 250 μg;

[0040] Cyanocobalamin: 1.05 μg;

[0041] Retinol: 400 μg RE;

[0042] Phytonadione: 30 μg;

[0043] Cholecalciferol: 12.5 μg;

[0044] α-Tocopherol: 5.55 mg α-TE;

[0045] Nicotinic acid: 2865 μg.

[0046] The compound minerals per 100 g of the milk powder composition contain: Magnesium: 380 mg; Iron: 90 mg; Zinc: 95 mg; Manganese: 2500 μg; Iodine: 550 μg; Copper: 2850 μg; Selenium: 200 μg; Calcium: 22 μg.

[0047] The probiotic is Bifidobacterium animalis subsp. lactis Bb-12.

[0048] The preparation method of the milk powder composition includes the following steps:

[0049] (1) Mix α-lactalbumin with no more than 1 / 2 amount of soybean oil and human milk oligosaccharide at room temperature for 1 - 2 min, and then perform high-speed shearing at 60 - 90 °C for 30 - 60 seconds to obtain a premix;

[0050] (2) Wet-mix and homogenize the premix obtained in step (1) with the remaining components and then dry to obtain the product; the homogenization is carried out under the condition of 65 ± 2 °C for secondary homogenization, with the primary homogenization pressure of 15 - 25 Mpa and the secondary homogenization pressure of 3 - 5 Mpa.

[0051] Example 2

[0052] A formula milk powder composition, the formula is as follows:

[0053] Raw material name Usage (parts) Human milk oligosaccharide (2'-FL) 7.2 OPN 0.8 Galactooligosaccharide 10 α-Lactalbumin 10 Lactoferrin 0.2 Compound vitamin 0.02 Lactose 51.76 Soybean oil 10 Coconut oil 10 Compound mineral 0.02 Total 100

[0054] The preparation method of this example is the same as that of Example 1.

[0055] Example 3

[0056] A formula milk powder composition, the main difference from Example 1 is that the formula is as follows:

[0057]

[0058]

[0059] Comparative Example 1

[0060] A formula milk powder composition has the following formula:

[0061] Raw material name Usage (parts) Human milk oligosaccharide (2'-FL) 1.8 OPN 0.1 Galactooligosaccharide 2.5 α-Lactalbumin 11.95 Lactoferrin 0.1 Compound vitamin 0.07 Lactose 52.86 Soybean oil 30 Compound mineral 0.6 Probiotic 0.02 Total 100

[0062] The difference between this comparative example and Example 1 is that the ratio of lactoferrin to OPN, human milk oligosaccharide, and galactooligosaccharide is 1:1:18:25.

[0063] Comparative Example 2

[0064] A formula milk powder composition has the following formula:

[0065] Raw material name Usage (parts) Human milk oligosaccharide (2'-FL) 1.8 OPN 0.1 Galactooligosaccharide 2.5 α-Lactalbumin 11.95 Lactoferrin 0.05 Compound vitamin 0.07 Lactose 52.91 Soybean oil 30 Compound mineral 0.6 Probiotic 0.02 Total 100

[0066] The difference between this comparative example and Example 1 is that α-lactalbumin is added to replace α-lactoalbumin.

[0067] Comparative Example 3

[0068] A formula milk powder composition has the following formula:

[0069]

[0070]

[0071] The difference between this comparative example and Example 1 is that 15 parts of medium-chain fatty acids are added to the formula, and at the same time, the content of soybean oil is adjusted down to 15 parts.

[0072] Comparative Example 4

[0073] A formula milk powder composition has the following formula:

[0074] Raw material name Usage (parts) Human milk oligosaccharide (2'-FL) 1.8 OPN 0.1 Galactooligosaccharide 2.5 α-Lactalbumin 12 Compound vitamin 0.07 Lactose 52.91 Soybean oil 30 Compound mineral 0.6 Probiotic 0.02 Total 100

[0075] The difference between this comparative example and Example 1 is that it does not contain lactoferrin.

[0076] Performance Test

[0077] Experimental Example 1

[0078] Dispersibility and Solubility Test of Milk Powder Composition

[0079] Method: Respectively take 15 g of the milk powder samples of each example and comparative example, dissolve them in 100 g of warm boiled water at 40 °C, stir for 15 s, and observe after standing for 10 min. As shown in Table 1 below.

[0080]

[0081]

[0082] According to the experimental results in Table 1, it can be seen that the milk powder composition provided by the present invention has good stability and no precipitation occurs.

[0083] Experimental Example 2

[0084] Cell experiment: Recovery and improvement effects on intestinal barrier function damage

[0085] In this experiment, a colon epithelial barrier model was constructed by co-culturing Caco-2 and HT-29 cells to study the recovery and improvement effects of each milk powder composition provided by the present invention on the intestinal barrier function damage caused by pro-inflammatory factors. At the same time, the fermentation metabolites of lactoferrin (LF) were used as a control to compare the differences in the effects. The experimental methods and steps are as follows:

[0086] 1. Construction and evaluation of the colon epithelial cell model

[0087] In the present invention, the human colon cancer cell lines Caco-2 and HT-29 cells were inoculated into the upper chamber of a 24-well Transwell hanging cell culture dish at a ratio of 9:1 and a density of 3.3×10 4 cells / well, and cultured in a cell culture incubator at 37°C, 5% (v / v) CO2 and saturated humidity with RPMI-1640 medium containing 10% fetal bovine serum, 1% penicillin-streptomycin and 1% non-essential amino acids for 20-21 days. The medium was changed every other day within the first seven days and every day after seven days. During the cell culture, the change in the transepithelial electrical resistance (TEER) value of the cells was measured and calculated using a Millicell-ERS cell resistance meter. Each well was measured three times from different directions, and the average value was used as the measured value of the resistance of each well. When the TEER of the Caco-2 / HT-29 co-cultured cells reached 300 Ω·cm 2 or above and remained basically stable, it indicated that the monolayer cells reached a fully differentiated state and the colon epithelial barrier was successfully constructed.

[0088] The experimental results showed that as the number of culture days increased, the TEER value of the Caco-2 / HT-29 co-cultured cells gradually increased, and reached 300 Ω·cm 2 and remained stable after 16 to 20 days of culture, that is, the colon epithelial cell model was successfully established, indicating that the Caco-2 / HT-29 (9:1) co-cultured cell model can be used to simulate the colon epithelial barrier.

[0089] 2. Construction of the intestinal barrier damage model

[0090] After the intestinal epithelial cell model was established, the cells were starved for 24 h with RPMI-1640 medium containing 1% fetal bovine serum. A mixed pro-inflammatory factor (Cytomix) (50 ng / ml TNF-α + 25 ng / mL IL-1β + 50 ng / ml IFN-γ) was added to the lower chamber of the Transwell culture dish for 24 h of intervention to stimulate the cells to produce inflammation and damage the intestinal barrier. The tightness of the co-cultured cell monolayer and the integrity of the intestinal barrier were evaluated by measuring and calculating the TEER value of the cells. If the TEER value decreased significantly, it indicated that the intestinal barrier injury model was successfully constructed.

[0091] 3. Effects of different milk powder compositions on the intestinal epithelial cell barrier function

[0092] After the intestinal epithelial cell model was established, each milk powder composition provided by the present invention was diluted to 1 g / mL with RPMI-1640 medium and added to the upper chamber of the Transwell. A mixed pro-inflammatory factor solution was added to the lower chamber for co-culture, and the cells were placed in a cell incubator for 24 h of intervention. The normal treatment group without intervention was the Control group, the treatment group with only the mixed pro-inflammatory factor solution added was the model control group, and the treatment group with acetate solution intervention was the positive control group. Three parallel wells were set for each treatment group. After the intervention, the TEER value of each well was measured and calculated, and then the cell supernatant in the upper chamber was collected and stored in an -80 °C refrigerator for subsequent analysis. Finally, the cells were lysed to extract total RNA for gene expression level detection. The specific operation steps were carried out according to the kit instructions.

[0093] The test results are shown in Table 2 below:

[0094] TEER (%) Control group 98％ Model control group 60％ Positive control group 75％ Example 1 83％ Example 2 80％ Example 3 81％ Comparative example 1 68％ Comparative example 2 73％ Comparative example 3 70％ Comparative example 4 66％

[0095] TEER is the ionic current resistance information across the cell monolayer and can be used as an evaluation parameter for the tightness of the cell monolayer and the integrity of the tight junctions between cells. It can be seen from the data in Table 2 that after the cells were stimulated with the mixed pro-inflammatory factor, the TEER value of the co-cultured cell model decreased significantly to 60%, indicating that the intestinal epithelial cells were damaged and the integrity of the intestinal barrier was disrupted. After the milk powder compositions provided in Examples 1-3 were added for intervention, the TEER value increased significantly, indicating that the fermentation metabolites in each group could protect the intestinal barrier function to a certain extent and were beneficial to the recovery of inflamed and damaged cells. Moreover, the milk powder compositions provided in Examples 1-3 had a better effect on increasing the TEER value than Comparative Examples 1-4 and had a higher ability to protect the integrity of the intestinal barrier.

[0096] Experimental Example 3

[0097] Animal experiment: Recovery and improvement effects on diarrhea caused by intestinal barrier function damage

[0098] Select 80 weaned piglets at 21 days old with diarrhea symptoms. Detect the levels of inflammatory factors IL-6, IL-1β, and TNF-α in the serum of each piglet by ELISA method. The specific operation steps are carried out according to the kit instructions.

[0099] The test results show that the levels of inflammatory factors in the serum of each piglet are significantly higher than those of piglets with normal defecation.

[0100] Randomly divide the above piglets into 8 groups, with 10 piglets in each group. The experimental grouping and treatment are as follows: 1) Control group, continue to feed the basic feed; 2) Experimental groups: Add 100 g / kg, 200 g / kg, and 500 g / kg of the milk powder compositions provided in the examples and comparative examples of the present invention to the basic feed respectively. During the experiment, all piglets have free access to water and food. The feeding period is 14 days, and the feces, body weight, and food intake of the piglets are collected and recorded every day. The experimental results are statistically shown in Table 3-4 below:

[0101] Table 3 Statistical results of the influence of the milk powder composition provided in Example 1 on the body weight of piglets

[0102]

[0103]

[0104] Table 4 Statistical results of the influence of the milk powder composition provided in Example 1 on the defecation of piglets

[0105]

[0106] Combined with the experimental data in Tables 2-3 above, it can be seen that the milk powder compositions provided in Examples 1-3 of the present invention all have a certain repair effect on the intestinal barrier damage caused by inflammatory factors, reduce the diarrhea ratio of piglets, and promote the growth of piglets. Although the milk powder compositions provided in Comparative Examples 1-4 contain human milk oligosaccharides, the effect of reducing diarrhea is poor, and thus the body weight of piglets grows slowly or even decreases.

[0107] Experimental Example 4

[0108] Animal experiment: Growth promotion experiment

[0109] Experimental animals: 80 clean-grade weaned SD rats at 15 d old, half male and half female, randomly divided into 8 groups, with 10 rats in each group, purchased from Shandong Lukang Pharmaceutical Co., Ltd.;

[0110] Experimental method: After 7 days of adaptive feeding with basal diet, the rats were individually caged. The temperature in the animal house was maintained at about 20 °C. They were fed once a day, and the feeding amount was 15% of the rat body weight. They had free access to distilled water and were raised for 4 weeks in total. Among them, the experimental group was fed with the samples of each example and comparative example, and the control example was fed with raw cow milk. The body length and weight on the 0th, 7th, 14th, 21st, and 28th days were recorded. The effects of different samples on the body length and weight of SD rats are shown in Table 5.

[0111] Table 5 Average body length and weight of rats at the beginning and end

[0112]

[0113] According to the experimental data in Table 4, it can be seen that the milk powder compositions provided in Examples 1-3 of the present invention are more conducive to absorption, and the growth promotion effect is better than that of Comparative Examples 1-4. Among them, the effect of Example 1 is the best. By comparing Examples 1-3 with Comparative Examples 1-4, it can be seen that when the ratio of lactoferrin, human milk oligosaccharide, OPN, and galactooligosaccharide is 1:2-4:2-50:50-120 and the human milk oligosaccharide is 2'-fucosyllactose, the performance has a better effect than other ratio ranges. When the composition does not contain lactoferrin or uses other nutritional components to form a composition with components such as human milk oligosaccharide, the absorption effect of the composition is significantly reduced, thereby affecting the growth of rats.

[0114] The above description of the embodiments is to enable those of ordinary skill in the art to understand and use the invention. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative efforts. Therefore, the present invention is not limited to the above embodiments, and the improvements and modifications made by those skilled in the art without departing from the scope of the present invention according to the disclosure of the present invention should be within the protection scope of the present invention.

Claims

1. An easily digestible and absorbable milk powder composition containing human milk oligosaccharides, characterized in that, It includes human milk oligosaccharides, OPN, galactooligosaccharides, lactoferrin, α-lactalbumin, compound vitamins, lactose, vegetable oil, and compound minerals; wherein the weight ratio of the lactoferrin, OPN, human milk oligosaccharides, and galactooligosaccharides is 1:2 - 4:2 - 50:4 - 100.

2. The milk powder composition according to claim 1, characterized in that, Based on the total weight of the milk powder composition being 100 parts, it includes 0.03 - 0.2 parts of lactoferrin, 0.02 - 10 parts of human milk oligosaccharides, 0.04 - 0.8 parts of OPN, 1 - 24 parts of galactooligosaccharides, 0.1 - 20 parts of α-lactalbumin, 0.02 - 1 part of compound vitamins, 30 - 60 parts of lactose, 2 - 30 parts of vegetable oil, and 0.02 - 2 parts of compound minerals.

3. The milk powder composition according to claim 2, characterized in that, Based on the total weight of the milk powder composition being 100 parts, it includes 0.03 - 0.2 parts of lactoferrin, 0.02 - 2 parts of human milk oligosaccharides, 0.04 - 0.8 parts of OPN, 1 - 6 parts of galactooligosaccharides, 0.1 - 20 parts of α-lactalbumin, 0.02 - 1 part of compound vitamins, 30 - 60 parts of lactose, 10 - 30 parts of vegetable oil, and 0.4 - 2 parts of compound minerals.

4. The milk powder composition according to any one of claims 1-3, characterized in that The human milk oligosaccharides include one or more of 2'-fucosyllactose, 3'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, lactose-dideminotetraose, and lactose-N-deminopentose I.

5. The milk powder composition according to any one of claims 1-3, characterized in that, The weight ratio of the human milk oligosaccharides to OPN is 18:

1.

6. The milk powder composition according to claim 5, wherein The human milk oligosaccharides are 2'-fucosyllactose.

7. The milk powder composition according to claim 1, characterized in that, The compound vitamins include one or more of vitamin C, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin A, vitamin K, vitamin D, vitamin E, and niacin.

8. The milk powder composition according to claim 1, characterized in that, The milk powder composition further includes probiotics. Based on the total weight of the milk powder composition being 100 parts, the content of the probiotics is 0.01 - 2 parts; and / or the probiotics are Bifidobacterium.

9. The milk powder composition according to claim 1, characterized in that, The compound minerals are one or more of sodium, potassium, copper, magnesium, iron, zinc, manganese, calcium, phosphorus, calcium, iodine, chlorine, and selenium.

10. A method for preparing an easily digestible and absorbable milk powder composition according to any one of claims 1 - 9, which includes the following steps: (1) Premix α-lactalbumin with no more than 1 / 2 amount of vegetable oil and human milk oligosaccharides to obtain a premix; (2) Mix and proportion the premix obtained in step (1) with the remaining components, homogenize, and then dry to obtain the product.

Images